Status:
COMPLETED
PET Study in Patients With Non-Hodgkin Lymphoma
Lead Sponsor:
Vanderbilt-Ingram Cancer Center
Conditions:
Lymphoma
Eligibility:
All Genders
Brief Summary
RATIONALE: Diagnostic procedures, such as fluorine 18-fludeoxyglucose positron emission tomography (PET) scans, may help doctors predict a patient's response to treatment and help plan the best treatm...
Detailed Description
OBJECTIVES: * To determine if a fluorine 18-fludeoxyglucose positron emission tomography scan, performed as early as day 30 after high-dose chemotherapy and autologous stem cell transplantation, may ...
Eligibility Criteria
Inclusion
- DISEASE CHARACTERISTICS:
- Diagnosis of non-Hodgkin lymphoma
- Has undergone high-dose chemotherapy followed by autologous stem cell transplantation at Vanderbilt University between March 1997 and August 2005
- Has undergone fluorine 18-fludeoxyglucose PET within 70 days prior to and/or at approximately 30 days and 100 days after high-dose chemotherapy and autologous stem cell transplantation
Exclusion
- PATIENT CHARACTERISTICS:
- Not specified
- PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
Key Trial Info
Start Date :
May 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 1 2009
Estimated Enrollment :
55 Patients enrolled
Trial Details
Trial ID
NCT00712556
Start Date
May 1 2008
End Date
March 1 2009
Last Update
February 26 2013
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Vanderbilt-Ingram Cancer Center - Cool Springs
Nashville, Tennessee, United States, 37064
2
Vanderbilt-Ingram Cancer Center at Franklin
Nashville, Tennessee, United States, 37064
3
Vanderbilt-Ingram Cancer Center
Nashville, Tennessee, United States, 37232-6838